Editorial
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Apr 15, 2024; 15(4): 598-605
Published online Apr 15, 2024. doi: 10.4239/wjd.v15.i4.598
Pancreatic surgery and tertiary pancreatitis services warrant provision for support from a specialist diabetes team
Vasileios K Mavroeidis, Jennifer Knapton, Francesca Saffioti, Daniel L Morganstein
Vasileios K Mavroeidis, Department of HPB Surgery, Bristol Royal Infirmary, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol BS2 8HW, United Kingdom
Vasileios K Mavroeidis, Department of Gastrointestinal Surgery, Southmead Hospital, North Bristol NHS Trust, Bristol BS10 5NB, United Kingdom
Vasileios K Mavroeidis, Jennifer Knapton, Department of Academic Surgery, Royal Marsden NHS Foundation Trust, London SW3 6JJ, United Kingdom
Francesca Saffioti, Department of Gastroenterology and Hepatology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, United Kingdom
Francesca Saffioti, UCL Institute for Liver and Digestive Health, University College London, London NW3 2PF, United Kingdom
Daniel L Morganstein, Department of Endocrinology, Chelsea and Westminster Hospital NHS Foundation Trust, London SW10 9NH, United Kingdom
Daniel L Morganstein, Department of Gastrointestinal Unit, Royal Marsden NHS Foundation Trust, London SW3 6JJ, United Kingdom
Author contributions: Mavroeidis VK conceptualised and designed the study, did the literature search and drafted the original manuscript; Knapton J and Saffioti F contributed to the literature search and revisions; Morganstein DL made critical revisions; all authors prepared the final draft and approved the final version.
Conflict-of-interest statement: Morganstein DL reports personal fees from Bristol Meyer Squibb, personal fees from MSD, personal fees from Roche. All other authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Vasileios K Mavroeidis, MD, MSc, FRCS, FACS, FICS, FSSO, MFSTEd, MICR, Academic Research, Surgeon, Department of HPB Surgery, Bristol Royal Infirmary, University Hospitals Bristol and Weston NHS Foundation Trust, Upper Maudlin St, Bristol BS2 8HW, United Kingdom. vasileios.mavroeidis@nhs.net
Received: December 30, 2023
Peer-review started: December 30, 2023
First decision: January 16, 2024
Revised: January 30, 2024
Accepted: March 1, 2024
Article in press: March 1, 2024
Published online: April 15, 2024
Processing time: 103 Days and 4.9 Hours
Abstract

Pancreatic surgery units undertake several complex operations, albeit with considerable morbidity and mortality, as is the case for the management of complicated acute pancreatitis or chronic pancreatitis. The centralisation of pancreatic surgery services, with the development of designated large-volume centres, has contributed to significantly improved outcomes. In this editorial, we discuss the complex associations between diabetes mellitus (DM) and pancreatic/periampullary disease in the context of pancreatic surgery and overall management of complex pancreatitis, highlighting the consequential needs and the indispensable role of specialist diabetes teams in support of tertiary pancreatic services. Type 3c pancreatogenic DM, refers to DM developing in the setting of exocrine pancreatic disease, and its identification and management can be challenging, while the glycaemic control of such patients may affect their course of treatment and outcome. Adequate preoperative diabetes assessment is warranted to aid identification of patients who are likely to need commencement or escalation of glucose lowering therapy in the postoperative period. The incidence of new onset diabetes after pancreatic resection is widely variable in the literature, and depends on the type and extent of pancreatic resection, as is the case with pancreatic parenchymal loss in the context of severe pancreatitis. Early involvement of a specialist diabetes team is essential to ensure a holistic management. In the current era, large volume pancreatic surgery services commonly abide by the principles of enhanced recovery after surgery, with inclusion of provisions for optimisation of the perioperative glycaemic control, to improve outcomes. While various guidelines are available to aid perioperative management of DM, auditing and quality improvement platforms have highlighted deficiencies in the perioperative management of diabetic patients and areas of required improvement. The need for perioperative support of diabetic patients by specialist diabetes teams is uniformly underlined, a fact that becomes clearly more prominent at all different stages in the setting of pancreatic surgery and the management of complex pancreatitis. Therefore, pancreatic surgery and tertiary pancreatitis services must be designed with a provision for support from specialist diabetes teams. With the ongoing accumulation of evidence, it would be reasonable to consider the design of specific guidelines for the glycaemic management of these patients.

Keywords: Pancreatectomy; Pancreatoduodenectomy; Whipple’s; Pancreatitis; Diabetes specialist; Type 3c pancreatogenic diabetes mellitus

Core Tip: In this editorial, we discuss the complex associations between diabetes mellitus and pancreatic/periampullary disease in the context of pancreatic surgery and overall management of complex pancreatitis, highlighting the consequential needs and the indispensable role of specialist diabetes teams in support of tertiary pancreatic services. In these settings, there is accumulating evidence that adequate glycaemic control at all stages improves outcomes, and that early involvement of specialist diabetes teams is of paramount importance to ensure a holistic management approach. The design of specific guidelines for the glycaemic management in these settings is warranted.